A double-blind, randomised, placebo controlled, sequential ascending dose study, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intra-articular doses of fasitibant in patients with symptomatic osteoarthritis of the knee.

Trial Profile

A double-blind, randomised, placebo controlled, sequential ascending dose study, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intra-articular doses of fasitibant in patients with symptomatic osteoarthritis of the knee.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2013

At a glance

  • Drugs Fasitibant chloride (Primary) ; Hyaluronic acid (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Biomarker
  • Acronyms ALBATROSS-2
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 24 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top